William Heiden, AMAG
January 9, 2020 03:51 PM EST
People

Cred­i­bil­i­ty shred­ded, AM­AG jet­ti­sons CEO and 2 drugs as it looks to re­or­ga­nize around a sal­vage plan

John Carroll

Editor & Founder

With its rev­enue num­bers in a tail­spin and a top drug un­der crit­i­cal re­view at the FDA fol­low­ing a failed con­fir­ma­to­ry study, AM­AG …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times